These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 26374686)

  • 21. Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems.
    Anderson ML; Califf RM; Sugarman J;
    Clin Trials; 2015 Jun; 12(3):276-86. PubMed ID: 25733677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current issues surrounding women and minorities in drug trials.
    Wermeling DP; Selwitz AS
    Ann Pharmacother; 1993; 27(7-8):904-11. PubMed ID: 8364277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of escalating regulatory requirements on the conduct of clinical research.
    Gordon BG; Kessinger A; Mann SL; Prentice ED
    Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of the Revised Common Rule for Human Participant Research.
    DeRenzo EG; Moss J; Singer EA
    Chest; 2019 Feb; 155(2):272-278. PubMed ID: 30312589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal-risk waiver of informed consent and exception from informed consent (Final Rule) studies at institutional review boards nationwide.
    Ernst AA; Weiss SJ; Nick TG; Iserson K; Biros MH
    Acad Emerg Med; 2005 Nov; 12(11):1134-7. PubMed ID: 16264084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical guide to understanding clinical research compliance.
    Neely JG; Paniello RC; Graboyes EM; Sharon JD; Grindler DJ; Nussenbaum B
    Otolaryngol Head Neck Surg; 2014 May; 150(5):716-21. PubMed ID: 24598406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When "minimal risk" research yields clinically-significant data, maybe the risks aren't so minimal.
    Sharp HM; Orr RD
    Am J Bioeth; 2004; 4(2):W32-6. PubMed ID: 15186687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA oversight of cell therapy clinical trials.
    Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
    Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The New 2019 Institutional Review Board Common Rule Update: Implications for Plastic Surgery Research.
    Crystal DT; Cuccolo NG; Ibrahim AMS; Neligan PC; Janis JE; Lin SJ
    Plast Reconstr Surg; 2020 May; 145(5):1323-1330. PubMed ID: 32332559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Governance of clinical research.
    Camilleri M; Tremaine WJ
    Am J Gastroenterol; 2012 Mar; 107(3):336-8. PubMed ID: 22388015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current issues in clinical research and the development of new pharmaceuticals.
    Goldhammer A
    Account Res; 2001; 8(4):283-91. PubMed ID: 12481798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surrogate consent for research involving adults with impaired decision making: survey of Institutional Review Board practices.
    Gong MN; Winkel G; Rhodes R; Richardson LD; Silverstein JH
    Crit Care Med; 2010 Nov; 38(11):2146-54. PubMed ID: 20802325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Privacy and confidentiality in pragmatic clinical trials.
    McGraw D; Greene SM; Miner CS; Staman KL; Welch MJ; Rubel A
    Clin Trials; 2015 Oct; 12(5):520-9. PubMed ID: 26374682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proxy and surrogate consent in geriatric neuropsychiatric research: update and recommendations.
    Kim SY; Appelbaum PS; Jeste DV; Olin JT
    Am J Psychiatry; 2004 May; 161(5):797-806. PubMed ID: 15121642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards.
    Knopman D; Alford E; Tate K; Long M; Khachaturian AS
    Alzheimers Dement; 2017 Aug; 13(8):940-946. PubMed ID: 28709585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When and how to include vulnerable subjects in clinical trials.
    Wendler D
    Clin Trials; 2020 Dec; 17(6):696-702. PubMed ID: 32806931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research on prisoners - a comparison between the IOM Committee recommendations (2006) and European regulations.
    Elger BS; Spaulding A
    Bioethics; 2010 Jan; 24(1):1-13. PubMed ID: 20017742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Food and Drug Administration and Institutional Review Board Approval of a Novel Prehospital Informed Consent Process for Emergency Research.
    McMullan J; Droege C; Strilka CR; Lindsell C; Linke MJ
    Prehosp Emerg Care; 2021; 25(4):512-518. PubMed ID: 32790539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethical challenges in neonatal research: Summary report of the ethics group of the newborn drug development initiative.
    Baer GR; Nelson RM;
    Clin Ther; 2006 Sep; 28(9):1399-407. PubMed ID: 17062312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical study reflections: another view: Commentary on: "Raising suspicions with the Food and Drug Administration: detecting misconduct".
    Spitzig P
    Sci Eng Ethics; 2010 Dec; 16(4):705-11. PubMed ID: 21052860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.